Original Research Articles

Clinicopathological Profile and Immunohistochemical Expression of CK19 and HBME-1 in Papillary Thyroid Carcinoma: A Descriptive Study from a Tertiary Care Centre in South India

Authors

  • P. Vidhya
  • M. Kanimozhi
  • Nivethitha Sridharan
Author affiliations
  • P. Vidhya Assistant Professor, Department of Pathology, Government Dharmapuri Medical College, Dharmapuri, Tamil Nadu, India
  • M. Kanimozhi Assistant Professor, Department of Pathology, Government Dharmapuri Medical College, Dharmapuri, Tamil Nadu, India
  • Nivethitha Sridharan Assistant Professor, Department of Pathology, SRM Medical College Hospital and Research Centre, Kattankulathur, Chengalpattu, Tamil Nadu, India

Downloads

Keywords:

  • Biomarkers, tumor
  • Hector Battifora mesothelial-1
  • Immunohistochemistry
  • Keratin-19
  • Thyroid cancer, papillary

Abstract

Background: Papillary thyroid carcinoma (PTC) is diagnosed mainly on its nuclear morphology, but follicular-patterned and less common variants can be difficult to recognise on routine histology. Cytokeratin 19 (CK19) and Hector Battifora mesothelial-1 (HBME-1) are widely used as adjunctive immunohistochemical markers. This study describes the clinicopathological profile of PTC and the expression of CK19 and HBME-1 across its histological variants. Methods: This retrospective descriptive study was carried out in the Department of Pathology, Karpaga Vinayaga Institute of Medical Sciences, Maduranthagam, Tamil Nadu, India, from July 2019 to June 2021. Thirty-three consecutive, histologically confirmed cases of PTC were included. Demographic and clinical details, histological variant, nuclear features, and immunohistochemical expression of CK19 and HBME-1 (scored 0 to 4+) were recorded and analysed descriptively. Results: Thirty-two patients (97.0%) were women, and 30 (90.9%) were aged 21-50 years. The follicular variant was the most common subtype (42.4%), followed by classical PTC (24.2%) and papillary microcarcinoma (21.2%). Optical nuclear clearing was present in all cases; nuclear grooves, psammoma bodies, intranuclear inclusions, and papillary architecture were seen in 84.8%, 51.5%, 42.4%, and 30.3% of cases, respectively. CK19 was expressed in all 33 cases (100%; 95% CI 89.6-100), with 3+ or 4+ staining in 29 (87.9%). HBME-1 was expressed in only 7 cases (21.2%; 95% CI 10.7-37.8). Conclusion: Nuclear morphology remains the mainstay of PTC diagnosis. CK19 was consistently and strongly expressed and is a useful adjunct in difficult cases, whereas HBME-1 positivity was low in this series; a negative HBME-1 stain should therefore not be used to exclude PTC.

0 0

Downloads

Download data is not yet available.

References

1. LiVolsi V. Papillary thyroid carcinoma: an update. Mod Pathol. 2011;24 Suppl 2(Suppl 2):S1-9. doi: 10.1038/modpathol.2010.129 PubMed · Google Scholar

2. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?. Cancer. 2017;123(3):372-81. doi: 10.1002/cncr.30360 PubMed · Google Scholar

3. Lloyd RV, Buehler D, Khanafshar E. Papillary thyroid carcinoma variants. Head Neck Pathol. 2011;5(1):51-6. doi: 10.1007/s12105-010-0236-9 PubMed · Google Scholar

4. Rosai J. Papillary thyroid carcinoma: a root-and-branch rethink. Am J Clin Pathol. 2008;130(5):683-6. doi: 10.1309/ajcpbf63bwmcyslw PubMed · Google Scholar

5. Kunjumon D, Upadhyaya K. Histopathological features of Papillary Thyroid Carcinoma with special emphasis on the significance of nuclear features in their diagnosis. Arch Med Health Sci. 2014;2(1):16. doi: 10.4103/2321-4848.133786 Google Scholar

6. Pusztaszeri M, Auger M. Update on the cytologic features of papillary thyroid carcinoma variants. Diagn Cytopathol. 2017;45(8):714-30. doi: 10.1002/dc.23703 PubMed · Google Scholar

7. Sak S. Variants of Papillary Thyroid Carcinoma: Multiple Faces of a Familiar Tumor. Turk Patoloji Derg. 2015;31 Suppl 1(Suppl 1):34-47. doi: 10.5146/tjpath.2015.01313 PubMed · Google Scholar

8. Nath MC, Erickson L. Aggressive Variants of Papillary Thyroid Carcinoma: Hobnail, Tall Cell, Columnar, and Solid. Adv Anat Pathol. 2018;25(3):172-9. doi: 10.1097/pap.0000000000000184 PubMed · Google Scholar

9. Liu H, Lin F. Application of immunohistochemistry in thyroid pathology. Arch Pathol Lab Med. 2015;139(1):67-82. doi: 10.5858/arpa.2014-0056-ra PubMed · Google Scholar

10. Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein A. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. Mod Pathol. 2006;19(12):1631-7. doi: 10.1038/modpathol.3800705 PubMed · Google Scholar

11. Sanuvada R, Nandyala R, Chowhan AK, Bobbidi P, Yootla M, Hulikal N, et al. Value of cytokeratin-19, Hector Battifora mesothelial-1 and galectin-3 immunostaining in the diagnosis of thyroid neoplasms. J Lab Physicians. 2018;10(2):200-7. doi: 10.4103/jlp.jlp_106_17 PubMed · Google Scholar

12. De Matos PS, Ferreira AP, De Oliveira Facuri F, Assumpção LVM, Metze K, Ward LS. Usefulness of HBME‐1, cytokeratin 19 and galectin‐3 immunostaining in the diagnosis of thyroid malignancy. Histopathology. 2005;47(4):391-401. doi: 10.1111/j.1365-2559.2005.02221.x Google Scholar

13. Rao R, Giriyan SS, Rangappa P. Clinicopathological profile of papillary carcinoma of thyroid: A 10-year experience in a tertiary care institute in North Karnataka, India. Indian J Cancer. 2017;54(3):514-8. doi: 10.4103/ijc.ijc_337_17 PubMed · Google Scholar

14. Karkuzhali P, Yogambal M, Kumar M. An Indian Tertiary Care Hospital Scenario of Papillary Carcinoma of Thyroid. J Clin Diagn Res. 2017;11(6):EC26-EC29. doi: 10.7860/jcdr/2017/27673.10095 PubMed · Google Scholar

15. Liu Z, Yu P, Xiong Y, Zeng W, Li X, Maiaiti Y, et al. Significance of CK19, TPO, and HBME-1 expression for diagnosis of papillary thyroid carcinoma. Int J Clin Exp Med. 2015;8(3):4369-74. PubMed · Google Scholar

16. Girardi FM, Barra MB, Zettler C. Variants of papillary thyroid carcinoma: association with histopathological prognostic factors. Braz J Otorhinolaryngol. 2013;79(6):738-44. doi: 10.5935/1808-8694.20130135 PubMed · Google Scholar

17. Yu XM, Schneider DF, Leverson G, Chen H, Sippel R. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases. Thyroid. 2013;23(10):1263-8. doi: 10.1089/thy.2012.0453 PubMed · Google Scholar

18. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016;2(8):1023-9. doi: 10.1001/jamaoncol.2016.0386 PubMed · Google Scholar

19. Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol. 2022;33(1):27-63. doi: 10.1007/s12022-022-09707-3 PubMed · Google Scholar

20. Shurbaji MS, Gupta PK, Frost J. Nuclear grooves: a useful criterion in the cytopathologic diagnosis of papillary thyroid carcinoma. Diagn Cytopathol. 1988;4(2):91-4. doi: 10.1002/dc.2840040202 PubMed · Google Scholar

21. Kumari N, Kalonia T, Malik A, Kumar A, Rao S. Value of Combined Cytomorphological Parameters in Improving Diagnostic Accuracy of Papillary Thyroid Carcinoma on Cytology - The Five Dependable Features. Indian J Endocrinol Metab. 2021;25(5):402-9. doi: 10.4103/ijem.ijem_389_21 PubMed · Google Scholar

22. Palo S, Biligi D. Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions. Malays J Pathol. 2017;39(1):55-67. PubMed · Google Scholar

23. Erdogan-Durmus S, Ozcan D, Yarikkaya E, Kurt A, Arslan A. CD56, HBME-1 and cytokeratin 19 expressions in papillary thyroid carcinoma and nodular thyroid lesions. J Res Med Sci. 2016;21:49. doi: 10.4103/1735-1995.183986 PubMed · Google Scholar

24. Saleh HA, Jin B, Barnwell J, Alzohaili O. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol. 2010;5:9. doi: 10.1186/1746-1596-5-9 PubMed · Google Scholar

Published

2026-11-17

Issue

Section

Original Research Articles

How to Cite

Vidhya, P., Kanimozhi, M., & Sridharan, N. (2026). Clinicopathological Profile and Immunohistochemical Expression of CK19 and HBME-1 in Papillary Thyroid Carcinoma: A Descriptive Study from a Tertiary Care Centre in South India. International Journal of Clinical and Biomedical Research, 11(4), 46-53. https://doi.org/10.31878/

Similar Articles

61-70 of 103

You may also start an advanced similarity search for this article.